Risk and outcomes of COVID-19 in patients with multiple sclerosis.

Irene Moreno-TorresVirginia Meca-LallanaLucienne Costa-FrossardCelia Oreja-GuevaraClara AguirreElda María Alba SuárezMayra Gómez MorenoLaura Borrega CaneloJulia Sabín MuñozYolanda AladroAlba CárcamoElena Rodríguez GarcíaJuan Pablo CuelloEnric MonrealSusana Sainz de la MazaFernando Pérez ParraFrancisco Valenzuela RojasCarlos López de Silanes de MiguelIgnacio CasanovaMaria Luisa Martínez GinesRosario BlascoAida Orviz GarcíaLuisa María Villar-GuimeransGuillermo Fernández-DonoVíctor ElviraCarmen SantiusteMercedes EspiñoJose Manuel García-Domínguez

Published in: European journal of neurology (2021)

Patients with MS do not appear to have greater risks of SARS-CoV-2 infection or severe COVID-19 outcomes compared with the general population. The decision to start or continue disease-modifying treatment should be based on a careful risk-benefit assessment.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
mass spectrometry
multiple sclerosis
ms ms
risk assessment
metabolic syndrome
adipose tissue
climate change
smoking cessation